Tech Company Financing Transactions
Janpix Funding Round
Janpix closed a $17.7 million funding round on 10/13/2017. Backers included GlaxoSmithKline, Johnson & Johnson Development Corporation and Medicxi Ventures.
Transaction Overview
Company Name
Announced On
10/13/2017
Transaction Type
Venture Equity
Amount
$17,650,000
Round
Undisclosed
Investors
Proceeds Purpose
The company will use the financing to fund its STAT research and take it into the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 14th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Janpix is discovering and developing inhibitors of Signal Transducer and Activator of Transcription proteins. Most members of this family of transcription factors have been known for some time and their relevance in certain cancers, in particular for STAT3 & STAT5, validated.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roman Fleck
Chief Scientific Officer
Patrick Gunning
VP - Bus. Development
Kay Noel
Browse more venture capital transactions:
Prev: 10/13/2017: Kobalt venture capital transaction
Next: 10/13/2017: Groupize venture capital transaction
Share this article
About Database of VC Transactions
We record all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs